Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity.

RAD51 is a key protein in the homologous recombination (HR) pathway of DNA double-strand break repair, and HR represents a novel target for cancer therapy. Because imatinib (Gleevec) has been reported to reduce RAD51 protein levels, we tested the clonogenic survival for RT112, H1299, PANC1, and PC3...

詳細記述

書誌詳細
主要な著者: Choudhury, A, Zhao, H, Jalali, F, Al Rashid, S, Ran, J, Supiot, S, Kiltie, A, Bristow, R
フォーマット: Journal article
言語:English
出版事項: 2009